Abstract
Purpose
To comparatively evaluate whether metastatic colorectal cancer (mCRC) patients with KRAS codon 13 mutations (codon 13 muts) can benefit from anti-EGFR treatment.
Methods
We performed a meta-analysis of relevant studies. Systematic searches of the PubMed, Embase, and Cochrane databases, as well as ASCO conference papers up to July 30, 2012, were retrieved, and the authors of included studies were contacted to obtain more individual data. Fixed effects meta-analytical models were used where indicated, and between-study heterogeneity was assessed. The primary study end points were the overall response rate (ORR). Secondary end points were progress-free survival (PFS) and overall survival (OS).
Results
A total of 7 studies were included in the final meta-analysis, consisting of 2,802 mCRC patients, 1,679 of whom were treated with anti-EGFR monoclonal antibodies. The ORR of mCRC patients with codon 13 mutation was 25.2 % (29/115), compared to 17.6 % (98/558) for other KRAS mutations (other mut) and 42.6 % (429/1,006) for KRAS WT patients. The overall pooled RR for ORRs of codon 13 mut versus other mut was 1.52 (95 % CI 1.10–2.09, P = 0.003), whereas the pooled RR for codon 13 mut versus WT was 0.61 (95 % CI 0.45–0.83, P = 0.002). The pooled progression-free survival (PFS) times were 6.4 months for codon 13 mut, 4.1 months for other mut, and 6.6 months for WT, whereas the pooled OS durations were 14.6, 11.8, and 17.3 months, respectively. Subgroup analysis was conducted on the basis of the line of treatment, anti-EGFR drug, study design, and detection method, respectively. The results implicated that KRAS codon 13 mut patients gain more benefit from Cetuximab in further line treatment.
Conclusions
Metastatic colorectal cancer patients with KRAS codon 13 mutations demonstrate a greater clinical response to anti-EGFR treatment than patients with other KRAS mutations.
Similar content being viewed by others
References
Siegel R, Ward E, Brawley O et al (2011) Cancer statistics, 2011. CA Cancer J Clin 61:212–236
Assenat E, Desseigne F, Thezenas S et al (2011) Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. Oncologist 16:1557–1564
Lamas MJ, Duran G, Gallardo E (2011) Anti-EGFR therapy in first-line colorectal cancer. Expert Rev Anticancer Ther 11:1499–1503
Saltz L, Badarinath S, Dakhil S et al (2011) Phase III trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX–Bevacizumab in colorectal cancer. Clin Colorectal Cancer 11:101–111
Ma ES, Wong CL, Law FB et al (2009) Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis. J Clin Pathol 62:886–891
Brink M, de Goeij AF, Weijenberg MP et al (2003) K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 24:703–710
Custsem EV, Kohne C-H, Hitre E, Zaluski J et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417
Bokemeyer C, Bondarenko I, Makhson A et al (2008) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671
US Food and Drug Administration (2011) Cetuximab (Erbitux) and panitumumab (Vectibix). http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm172905.htm. Accessed Mar 12
European Medicines Agency (2011) Committee for medicinal products for human use postauthorisation summary of positive opinion for Erbitux. 30 May 2008. http://www.emea.europa.eu/pdfs/human/opinion/erbitux_28040208en.pdf. Accessed Mar 12
Frattini M, Saletti P, Romagnani E et al (2007) PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 97:1139–1145
Moroni M, Veronese S, Benvenuti S et al (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6:279–286
De Roock W, Jonker DJ, Di Nicolantonio F et al (2010) Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304:1812–1820
Tejpar S, Celik I, Schlichting M et al (2012) Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol 30:3570–3577
Wells G, Shea B, O’Connell D (2011) The Newcastle–Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed Oct 20
DerSimon R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188
Egger M, Smith GD, Schneider M (1997) Bias in meta analysis detected by a simple, graphical test. BMJ 315:629–634
Molinari F, Felicioni L, Buscarino M et al (2011) Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 17:4901–4914
Licar A, Cerkovnik P, Ocvirk J et al (2010) KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment. Int J Oncol 36:1137–1144
Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67:2643–2648
Modest DP, Jung A, Moosmann N et al (2011) The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial. Int J Cancer 131:980–986
Bando H, Yoshino T, Shinozaki E et al (2011) Clinical outcome in patients with metastatic colorectal cancer harboring KRAS p.G13D mutation treated with cetuximab. J Clin Oncol 29 [abstr 448]
Schlessinger J (2002) Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110:669–672
Bianco R, Shin I, Ritter CA et al (2003) Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22:2812–2822
Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127–137
Peeters M, Douillard JY, Cutsem EV et al (2012) Mutant (MT) KRAS codon 12 and 13 alletes in patients (pts) with metastatic colorectal cancer (mCRC): assessment as prognostic and predictive biomarkers of response to panitumumab (pmab). J Clin Oncol 30(suppl 4; abstr 383)
Acknowledgments
This work was supported by Zhejiang Province Education Scientific Project (Y201120237 and Y200805053).
Conflict of interest
The authors declare that they have no competing interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, J., Ye, Y., Sun, H. et al. Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis. Cancer Chemother Pharmacol 71, 265–272 (2013). https://doi.org/10.1007/s00280-012-2005-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-012-2005-9